CN102688196B - 一种含有奥美拉唑的颗粒及其制备方法 - Google Patents
一种含有奥美拉唑的颗粒及其制备方法 Download PDFInfo
- Publication number
- CN102688196B CN102688196B CN201210157610.3A CN201210157610A CN102688196B CN 102688196 B CN102688196 B CN 102688196B CN 201210157610 A CN201210157610 A CN 201210157610A CN 102688196 B CN102688196 B CN 102688196B
- Authority
- CN
- China
- Prior art keywords
- omeprazole
- sodium bicarbonate
- granule
- preparation
- dry granulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 238000002360 preparation method Methods 0.000 title abstract description 38
- 229960000381 omeprazole Drugs 0.000 claims abstract description 97
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 59
- 239000013078 crystal Substances 0.000 claims abstract description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 30
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 13
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 238000007908 dry granulation Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002775 capsule Substances 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 24
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 18
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 13
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 abstract 2
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 238000005755 formation reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229940054825 sodium bicarbonate 1100 mg Drugs 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 229940071621 omeprazole / sodium bicarbonate Drugs 0.000 description 5
- 229940096382 omeprazole 40 mg Drugs 0.000 description 5
- UUYQXLQNUVEFGD-UHFFFAOYSA-M sodium;hydrogen carbonate;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].OC([O-])=O.N1C2=CC(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C UUYQXLQNUVEFGD-UHFFFAOYSA-M 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940080133 omeprazole 20 mg Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012154 short term therapy Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 238000010237 hybrid technique Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- -1 Antacid sodium bicarbonate Chemical class 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241001635574 Sabatia angularis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210157610.3A CN102688196B (zh) | 2012-05-21 | 2012-05-21 | 一种含有奥美拉唑的颗粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210157610.3A CN102688196B (zh) | 2012-05-21 | 2012-05-21 | 一种含有奥美拉唑的颗粒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102688196A CN102688196A (zh) | 2012-09-26 |
CN102688196B true CN102688196B (zh) | 2014-02-19 |
Family
ID=46854045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210157610.3A Active CN102688196B (zh) | 2012-05-21 | 2012-05-21 | 一种含有奥美拉唑的颗粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102688196B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103006691B (zh) * | 2013-01-05 | 2014-10-08 | 青岛大学 | 一种含奥美拉唑碳酸氢钠复方胶囊制剂 |
CN107913255A (zh) * | 2016-10-10 | 2018-04-17 | 北京阜康仁生物制药科技有限公司 | 一种含有奥美拉唑的片剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
WO2008067037A2 (en) * | 2006-10-05 | 2008-06-05 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
CN101455629A (zh) * | 2008-11-17 | 2009-06-17 | 马晶 | 含有奥美拉唑的口服固体制剂 |
CN101756935A (zh) * | 2008-12-26 | 2010-06-30 | 上海医药科技发展有限公司 | 一种奥美拉唑胶囊及其制备方法 |
-
2012
- 2012-05-21 CN CN201210157610.3A patent/CN102688196B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102688196A (zh) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103813785B (zh) | 新的治疗阿片样物质依赖的抗滥用药物组合物 | |
CA2720658C (en) | Improved formulations for poorly permeable active pharmaceutical ingredients | |
TW201000472A (en) | New solid pharmaceutical formulations comprising BIBW 2992 | |
WO2015032873A1 (en) | High-load pharmaceutical compositions comprising abiraterone acetate | |
TW201111368A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan, and amlodipine, their preparation and their therapeutic application | |
AU2013365715B2 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
CN103070864A (zh) | 一种瑞格列奈和盐酸二甲双胍药物组合物及其制备方法 | |
CA2696977C (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
CN101626755B (zh) | 包含酸不稳定药物的双单元片剂 | |
KR20150044027A (ko) | 결장 배출의 용도를 위한 제제 및 제조 제제의 방법 | |
CN102307575A (zh) | 含醋氯芬酸的控释口服药制剂及其制造方法 | |
CN102688196B (zh) | 一种含有奥美拉唑的颗粒及其制备方法 | |
US20130146496A1 (en) | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation | |
TWI721938B (zh) | 醫藥劑型 | |
TW200906397A (en) | Process for preparing pramipexole dihydrochloride tablets | |
CA2517120C (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
CN1321642C (zh) | 泮托拉唑钠肠溶微丸 | |
CN102764254A (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN107913255A (zh) | 一种含有奥美拉唑的片剂及其制备方法 | |
EP3236950B1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
CN103432082A (zh) | 氨基葡萄糖组合物及其制备方法 | |
CN105267171B (zh) | 盐酸伊托必利组合物 | |
Akhlaq et al. | Formulation and in-vitro evaluation of Flurbiprofen controlled release matrix tablets using cellulose derivative polymers | |
WO2023139312A1 (en) | Pharmaceutical composition of a cyp11a1 inhibitor | |
KR20230124504A (ko) | 라베프라졸 및 탄산수소나트륨을 포함하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 310012 West Lake international science and technology building, No. 391 Wen two road, Hangzhou, Zhejiang, C910, Xihu District Applicant after: HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE CO., LTD. Address before: 310012 West Lake international science and technology building, No. 391 Wen two road, Hangzhou, Zhejiang, C910, Xihu District Applicant before: Hangzhou Huadong Medicine Group Biological Engineering Research Institute Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BIOENGINEERING INST. CO., LTD., HANGZHOU EAST-CHINA MEDICINE GROUP TO: NEW DRUG RESEARCH INSTITUTE CO., LTD. OF HANGZHOU HUADONG MEDICINE GROUP |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |